Cellular Resistance Mechanisms in Cancer and the New Approaches to Overcome Resistance Mechanisms Chemotherapy

Overview

Journal Saudi Med J

Specialty General Medicine

Date 2023 Apr 16

PMID 37062547

Authors

Hajir A Al Saihati

Ali A Rabaan

Affiliations

Soon will be listed here.

Abstract

Despite major advancements in cancer healing approaches over the last few decades, chemotherapy remains the most popular malignancy treatment. Chemotherapeutic drugs are classified into many kinds based on their mechanism of action. Multidrug resistance (MDR) is responsible for approximately 90% of fatalities in malignancy cases treated with standard chemotherapeutics or innovative targeted medicines. Many innovative prospective anti-cancer medicines displayed high anti-cancer efficacy in a single application. However, combining them with other medications improves cancer treatment efficacy. This supports the belief that a combination of drugs is significantly more effective than a single medicine. Due to the intricacy of MDR processes and the diversity of tumor illnesses, there will rarely be a single medicine that can be utilized to treat all types of cancer. Finding new medications that can reverse MDR in malignancy cells will augment efficacy of chemotherapeutic agents and allow us to treat cancers that are now incurable.

Citing Articles

Herbal drug‑based nanotherapy for hepatocellular carcinoma: Quercetin‑contained nanocarrier as a multipurpose therapeutic agent against hepatocellular carcinoma (Review).

Batsukh T, Tsend-Ayush A Biomed Rep. 2024; 22(2):29.

PMID: 39720296 PMC: 11668132. DOI: 10.3892/br.2024.1907.

Blood Cell Membrane-Coated Nanomaterials as a Versatile Biomimetic Nanoplatform for Antitumor Applications.

Shen H, Ouyang Y, Zhang L, Li J, Wang S Nanomaterials (Basel). 2024; 14(21).

PMID: 39513837 PMC: 11548044. DOI: 10.3390/nano14211757.

Physicochemical Properties and Release Study of Antimetabolite-Incorporated Stearoyl Chitosan.

Marlina A, Misran M ACS Omega. 2023; 8(43):40494-40507.

PMID: 37929136 PMC: 10620914. DOI: 10.1021/acsomega.3c05108.

References

Chandrasekhar C, Santhosh Kumar P, Sarma P . Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep. 2019; 9(1):2412. PMC: 6382822. DOI: 10.1038/s41598-019-38672-x. View

Salama B, El-Sherbini E, El-Sayed G, El-Adl M, Kanehira K, Taniguchi A . The Effects of TiO Nanoparticles on Cisplatin Cytotoxicity in Cancer Cell Lines. Int J Mol Sci. 2020; 21(2). PMC: 7013663. DOI: 10.3390/ijms21020605. View

Pathania S, Bhatia R, Baldi A, Singh R, Rawal R . Drug metabolizing enzymes and their inhibitors' role in cancer resistance. Biomed Pharmacother. 2018; 105:53-65. DOI: 10.1016/j.biopha.2018.05.117. View

Wu C, Hsiao S, Huang Y, Hung L, Yu Y, Chang Y . Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers (Basel). 2020; 12(1). PMC: 7017071. DOI: 10.3390/cancers12010195. View

Wojtaszek J, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K . A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019; 178(1):152-159.e11. PMC: 6644000. DOI: 10.1016/j.cell.2019.05.028. View

Alkema N, Wisman G, van der Zee A, van Vugt M, de Jong S . Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resist Updat. 2016; 24:55-69. DOI: 10.1016/j.drup.2015.11.005. View

Chen H, Chung Y, Li C, Chang Y, Wang C, Lee H . Taxifolin Resensitizes Multidrug Resistance Cancer Cells via Uncompetitive Inhibition of P-Glycoprotein Function. Molecules. 2018; 23(12). PMC: 6321030. DOI: 10.3390/molecules23123055. View

Planells-Cases R, Lutter D, Guyader C, Gerhards N, Ullrich F, Elger D . Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 2015; 34(24):2993-3008. PMC: 4687416. DOI: 10.15252/embj.201592409. View

Bonneau C, Gurard-Levin Z, Andre F, Pusztai L, Rouzier R . Predictive and Prognostic Value of the TauProtein in Breast Cancer. Anticancer Res. 2015; 35(10):5179-84. View

10.

Wojtuszkiewicz A, Raz S, Stark M, Assaraf Y, Jansen G, Peters G . Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. Int J Cancer. 2015; 138(7):1645-56. DOI: 10.1002/ijc.29919. View

11.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

12.

Desideri E, Ciccarone F, Ciriolo M . Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy. Nutrients. 2019; 11(8). PMC: 6724225. DOI: 10.3390/nu11081926. View

13.

Schramm A, de Gregorio N, Widschwendter P, Fink V, Huober J . Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel). 2015; 10(3):173-8. PMC: 4569208. DOI: 10.1159/000431029. View

14.

Zhao Z, Shilatifard A . Epigenetic modifications of histones in cancer. Genome Biol. 2019; 20(1):245. PMC: 6868810. DOI: 10.1186/s13059-019-1870-5. View

15.

Gioia U, Francia S, Cabrini M, Brambillasca S, Michelini F, Jones-Weinert C . Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs. Sci Rep. 2019; 9(1):6460. PMC: 6478851. DOI: 10.1038/s41598-019-42892-6. View

16.

Xu H, Dephoure N, Sun H, Zhang H, Fan F, Liu J . Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4. J Proteome Res. 2015; 14(6):2480-91. DOI: 10.1021/acs.jproteome.5b00004. View

17.

Yu Y, Gaillard S, Phillip J, Huang T, Pinto S, Tessarollo N . Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell. 2015; 28(1):82-96. PMC: 5257279. DOI: 10.1016/j.ccell.2015.05.009. View

18.

Lv H, Zhen C, Liu J, Yang P, Hu L, Shang P . Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy. Oxid Med Cell Longev. 2019; 2019:3150145. PMC: 6590529. DOI: 10.1155/2019/3150145. View

19.

Taddia L, DArca D, Ferrari S, Marraccini C, Severi L, Ponterini G . Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resist Updat. 2015; 23:20-54. DOI: 10.1016/j.drup.2015.10.003. View

20.

Albarakati N, Abdel-Fatah T, Doherty R, Russell R, Agarwal D, Moseley P . Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol. 2014; 9(1):204-17. PMC: 5528668. DOI: 10.1016/j.molonc.2014.08.001. View